Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Richard J. Morales"'
Publikováno v:
Biopharmaceutics & Drug Disposition. 18:665-680
Selegiline is a selective, irreversible inhibitor of MAO-B, used in the treatment of Parkinson's disease, either alone or as an adjunct to L-DOPA. The sole recommended dosing regimen is 5 mg given in the morning and at noon with breakfast and lunch.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42224857ace2b7325513fc8da5d4743f
https://doi.org/10.1002/(sici)1099-081x(199711)18:8<665::aid-bdd47>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199711)18:8<665::aid-bdd47>3.0.co
Publikováno v:
Biopharmaceutics & Drug Disposition. 18:567-584
Selegiline (SEL) is a selective, irreversible inhibitor of MAO-B, used in the treatment of Parkinson's disease, either alone or as an adjunct to L-DOPA. Selegiline hydrochloride (HCl) undergoes significant first-pass metabolism following oral adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be9251c6b148004d15191e204d51b081
https://doi.org/10.1002/(sici)1099-081x(199710)18:7<567::aid-bdd49>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199710)18:7<567::aid-bdd49>3.0.co
Publikováno v:
American Journal of Therapeutics. 4:229-238
Ipriflavone (IP) is a derivative of naturally occurring isoflavones and is marketed as Osteofix for the treatment of osteoporosis in Europe. IP has poor aqueous solubility, and the Osteofix compressed tablet has poor and variable bioavailability (F )
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f44574891aecd5c97307595db3ca6725
https://doi.org/10.1097/00045391-199707000-00003
https://doi.org/10.1097/00045391-199707000-00003
Autor:
A.R. Disanto, Thomas J. Hochadel, Richard J. Morales, Jeffrey S. Barrett, John Darnow, Shashank Rohatagi, Albert J. Azzaro, Sara K. Watson, Kimberly E. DeWitt
Publikováno v:
The Journal of Clinical Pharmacology. 37:238-247
Orally administered selegiline hydrochloride is a selective monoamine oxidase type B inhibitor at the recommended regimen of 10 mg/day, but it loses selectivity at higher doses. In bypassing first-pass metabolism, a 24-hour application of transdermal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9fd22f3389e7b57c419b09f6aa1b331
https://doi.org/10.1002/j.1552-4604.1997.tb04786.x
https://doi.org/10.1002/j.1552-4604.1997.tb04786.x
Autor:
Richard J. Morales, Matthew J. Palazzolo, Peter J. Thomford, A.R. Disanto, Jeffrey S. Barrett, Eric M. Larsen
Publikováno v:
Biopharmaceutics & Drug Disposition. 18:165-184
The toxicology and toxicokinetics of a selegiline transdermal system (STS) were evaluated in a 3 month dog study of daily 24h applications of placebo 4, 8, or 12 STSs in 32 male and 32 female beagle dogs. Each STS delivered approximately 5 mg selegil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4020546a503c18ef717e0b6cbaa32749
https://doi.org/10.1002/(sici)1099-081x(199703)18:2<165::aid-bdd14>3.0.co
https://doi.org/10.1002/(sici)1099-081x(199703)18:2<165::aid-bdd14>3.0.co
Autor:
Shashank Rohatagi, Jeffrey S. Barrett, Richard J. Morales, Kimberly E. DeWitt, Anthony R. DiSanto
Publikováno v:
American Journal of Therapeutics. 3:298-313
The pharmacokinetics of oral selegiline hydrochloride were examined in two crossover studies in healthy volunteers: a 5-mg b.i.d. administration in the fed-versus-fasted state and a 5-mg b.i.d. versus 10-mg q.d. multiple-dose administration. Food inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcf2c1df90dab72c860c3b4dee95bfc0
https://doi.org/10.1097/00045391-199604000-00008
https://doi.org/10.1097/00045391-199604000-00008
Autor:
Anthony R. DiSanto, Jeffrey S. Barrett, Sara K. Watson, Thomas J. Hochadel, Richard J. Morales, Kimberly E. DeWitt, Shashank Rohatagi
Publikováno v:
American journal of therapeutics. 3(10)
This open-label, two-phase cross-over study compared the safety and pharmacokinetics of transdermally administered selegiline and orally administered selegiline hydrochloride in elderly men and women (n = 6/gender). Single oral doses of 10 mg selegil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464012f68d05011bd688752f784aea39
https://pubmed.ncbi.nlm.nih.gov/11862224
https://pubmed.ncbi.nlm.nih.gov/11862224